# Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)

> **NCT07331883** · PHASE2 · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 35 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** Sintilimab plus bevacizumab biosimilar

## Key facts

- **NCT ID:** NCT07331883
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-17
- **Primary completion:** 2028-12-01
- **Final completion:** 2029-03-31
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07331883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07331883, "Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07331883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*